Alnylam Partners with Sanofi’s Genzyme to Advance its ALN-TTR Programme in Asia-Pacific
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 11 (Table of Contents)
Published: 12 Nov-2012
DOI: 10.3833/pdr.v2012.i11.1833 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi’s Genzyme has licensed rights to develop and commercialise RNAi therapeutics targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific territories from Alnylam Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS